All research
Selank: GABAergic Signaling in Rodent CNS Models
Cognitive Research
Research Brief

Selank: GABAergic Signaling in Rodent CNS Models

Tuftsin-derived heptapeptide studied for GABAergic tone, BDNF expression, and stress-response modulation.

Branded Blends Research TeamJuly 22, 20256 min read
Key Findings
  • 1Stable heptapeptide analog of tuftsin with retained CNS activity.
  • 2Modulates GABA-A subunit expression and serotonin turnover.
  • 3Altered elevated-plus-maze / open-field behavior in rodent models without sedation or motor impairment.
  • 4Upregulates BDNF and modulates IL-6 / IFN-γ expression.

Origin

Selank is a synthetic heptapeptide developed at the Institute of Molecular Genetics in Russia as a stable analog of the endogenous immunomodulator tuftsin. The C-terminal Pro-Gly-Pro extension dramatically increases plasma stability while preserving the parent peptide's CNS activity.

GABAergic and Serotonergic Modulation

Rodent models show that Selank shifts the expression of GABA-A receptor subunits and increases serotonin turnover in the hippocampus and frontal cortex. The behavioral signature in elevated-plus-maze and open-field paradigms is anxiolytic without the sedation or motor impairment typical of benzodiazepines.

BDNF and Immunomodulation

Selank upregulates BDNF expression in the hippocampus and modulates expression of cytokines IL-6 and IFN-γ — bridging its neurotrophic and tuftsin-derived immune activity. Small human studies in generalized anxiety populations report reductions in symptom scales, though sample sizes remain limited.

Research Use Only — All peptides and research findings referenced are intended strictly for in-vitro laboratory research. Not for human consumption, diagnostic, therapeutic, or veterinary use.
Related Briefs

Continue reading

Research Use Only

Not for human or veterinary consumption, diagnostic, or therapeutic use. Full disclaimer